icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials
 
 
  Reported by Jules Levin
AASLD - The Liver Meeti ng of the American Associati on for the Study of Liver Diseases (AASLD), October 20-24, 2017, Washington, District of Columbia, United States
 
Graham R Foster1, Sarah Kopecky-Bromberg2, Yang Lei2, Roger Trinh2, Federico Mensa2 1Hepatology Unit, Queen Mary University of London, London, United Kingdom; 2AbbVie Inc., North Chicago, Illinois, United States

1027171

1027172

1027173

1027174

1027175

1027176

1027177

1027178

1027179